The Clinical Trials on Alzheimer's Disease (CTAD) meeting will be held in San Francisco, between the 29th November and 2nd December. Following the FDA approval of Aduhelm (aducanumab) and the recent clinical data released for lecanemab, the Alzheimer's disease (AD) therapy area is becoming increasingly exciting. IXICO are firmly entrenched in supporting the development of new AD therapeutics and we believe the company's strong presence in this area will drive value in the company over a long-ter ....
